1369852-71-0

Usage

Uses

Used in Pharmaceutical Industry:
(S)-5-[5-(3,4,5-trichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide is used as a potential pharmaceutical agent due to its structural complexity and diverse functional groups, which may allow for targeted interactions with biological systems and the development of new therapeutics.
Used in Pesticide Development:
In the agricultural industry, (S)-5-[5-(3,4,5-trichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide is used as a potential pesticide, leveraging its chemical properties to control or eliminate pests, thereby enhancing crop protection and yield.
Used in Research and Development:
(S)-5-[5-(3,4,5-trichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-3-methyl-thiophene-2-carboxylic acid [(2,2,2-trifluoro-ethylcarbamoyl)-methyl]-amide is utilized in research and development settings to explore its potential applications in various fields, including drug discovery, material science, and chemical engineering, due to its unique structural features and functional group diversity.

Upstream product

• 23806-24-8 3-methyl-2-thiophenecarboxylic acid 
• 1613733-74-6 C₁₆H₉Cl₃F₃NO₃S 
• 1171331-39-7 1-oxo-1-N-(2,2,2-trifluoroethyl)-1,2-diaminoethane hydrochloride 
• 38239-45-1 5-bromo-3-methyl-thiophene-2-carboxylic acid 
• 1613733-73-5 C₁₅H₈BrCl₃F₃NOS 
• 158401-00-4 1-(3,4,5-trichloro-phenyl)-2,2,2-trifluoro-ethanone 
• 859199-06-7 1-(5-bromo-4-methylthiophen-2-yl)ethan-1-one 

Relevant academic research and scientific papers

PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF

The present disclosure provides processes for making enantiomerically pure isoxazoline compounds of formula (1), (1). The present disclosure also provides processes for making enantiomerically pure isoxazoline compounds of formula (1) characterized by improving the enantiomeric purity of 3-methyl-5-[(5S)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxylic acid by crystallization.

Preparation method of isoxazoline insecticide

The invention relates to a preparation method of an isoxazoline insecticide, which relates to the technical field of chemical industry, and comprises the following steps: 1) coupling reaction: mixingan intermediate 1 with nitromethane in a solvent, adding a palladium catalyst and a ligand to carry out catalytic coupling, reacting, and separating and purifying to obtain an intermediate 2; 2) cyclization reaction: mixing the intermediate 2 and an intermediate 3, adding the mixture into a mixed solution of a dehydrating agent and alkali, carrying out full cyclization reaction, and purifying to obtain an intermediate 4; and 3) condensation reaction: mixing the intermediate 4 and an intermediate 5, adding a condensing agent, carrying out full condensation reaction, and carrying out separationand purification to obtain an isoxazoline compound 6. The method has the advantages of short reaction route, accessible raw materials, fewer three wastes and high purity of the purified product, and is suitable for industrial production.

PROCESS FOR THE ENANTIOMERIC ENRICHMENT OF DIARYLOXAZOLINE DERIVATIVES

The present invention concerns a process for the manufacture of the S-enantiomer of a compound of formula (I) wherein the variables are as defined in the specification and claims, comprising the steps of (A) separating a racemic compound of formula (II) wherein R', R and R' and Y are as defined above and Z is Q; or is halogen, amino, carboxy (-COOH); into the enantiomers and collecting the S-enantiomer; (B) if Z is other than Q, converting the S-enantiomer of formula (II) from step (A) to a S- enantiomer of formula (I); (C) racemizing the R-enantiomer of formula (II) from step (A) in a reaction medium comprising a base and an aprotic organic solvent at a temperature of from 30°C to 150°C, and (D) subjecting the racemate from step (C) to a further manufacturing cycle comprising step (A) and optionally (B). Accordingly, a cyclic process is provided, wherein the undesired enantiomer of a first enantiomer separation step is racemized and then phased in a further enantiomer separation step.